keyword
https://read.qxmd.com/read/38685088/acute-respiratory-failure-due-to-pulmonary-exacerbation-in-children-with-cystic-fibrosis-admitted-in-a-pediatric-intensive-care-unit-outcomes-and-factors-associated-with-mortality
#1
JOURNAL ARTICLE
David Drummond, Charlotte Roy, Matthieu Cornet, Julie Bucher, Véronique Boussaud, Françoise Le Pimpec-Barthes, Margaux Pontailler, Olivier Raisky, Vanessa Lopez, Claudio Barbanti, Romain Guillemain, Sylvain Renolleau, Marion Grimaud, Mehdi Oualha, Laure de Saint Blanquat, Isabelle Sermet-Gaudelus
BACKGROUND: Children with advanced pulmonary disease due to cystic fibrosis (CF) are at risk of acute respiratory failure due to pulmonary exacerbations leading to their admission to pediatric intensive care units (PICU). The objectives of this study were to determine short and medium-term outcomes of children with CF admitted to PICU for acute respiratory failure due to pulmonary exacerbation and to identify prognosis factors. METHODS: This retrospective monocentric study included patients less than 18 years old admitted to the PICU of a French university hospital between 2000 and 2020...
April 29, 2024: Respiratory Research
https://read.qxmd.com/read/38685084/association-between-arachidonate-lipoxygenase-15-c-292%C3%A2-c%C3%A2-%C3%A2-t-gene-polymorphism-and-non-cystic-fibrosis-bronchiectasis-in-children-a-pilot-study-on-the-effects-on-airway-lipoxin-a4-and-disease-phenotype
#2
JOURNAL ARTICLE
Mahitab Morsy Hussein, Eman Mahmoud Fouda, Yasmine Shehab, Enas Samir Nabih, Ahmed Mohamed Osman, Sally Raafat Ishak
BACKGROUND: Persistent airway inflammation is a central feature of bronchiectasis. Arachidonate 15-lipoxygenase (ALOX-15) controls production of endogenous lipid mediators, including lipoxins that regulate airway inflammation. Mutations at various positions in ALOX-15 gene can influence airway disease development. We investigated association between ALOX-15,c.-292 C > T gene polymorphism and bronchiectasis unrelated to cystic fibrosis in Egyptian children. Also, lipoxin A4 (LXA4) level in bronchoalveolar lavage (BAL) was studied in relation to polymorphism genotypes and disease phenotypes determined by clinical, pulmonary functions, and radiological severity parameters...
April 29, 2024: Italian Journal of Pediatrics
https://read.qxmd.com/read/38685004/clinical-significance-and-potential-pathogenesis-of-vcan-in-adult-non-cystic-fibrosis-bronchiectasis-a-retrospective-study
#3
JOURNAL ARTICLE
Wan-Ying Huang, Kang-Kang Hong, Rong-Quan He, Jing Luo, Zhi-Guang Huang, Chu-Yue Zhang, Yang Xu, Chong-Xi Bao, Liang-Ming Zhang, Gang Chen, Jin-Liang Kong
BACKGROUND: The pathogenesis of adult non-cystic fibrosis (CF) bronchiectasis is complex, and the relevant molecular mechanism remains ambiguous. Versican (VCAN) is a key factor in inflammation through interactions with adhesion molecules. This study constructs a stable panoramic map of mRNA, reveals the possible pathogenesis of bronchiectasis, and provides new ideas and methods for bronchiectasis. METHODS: Peripheral blood and tissue gene expression data from patients with bronchiectasis and normal control were selected by bioinformatics analysis...
April 29, 2024: BMC Pulmonary Medicine
https://read.qxmd.com/read/38681615/longitudinal-improvements-in-clinical-and-functional-outcomes-following-initiation-of-elexacaftor-tezacaftor-ivacaftor-in-patients-with-cystic-fibrosis
#4
JOURNAL ARTICLE
Kadambari Vijaykumar, Hui Min Leung, Amilcar Barrios, Justin Wade, Heather Y Hathorne, David P Nichols, Guillermo J Tearney, Steven M Rowe, George M Solomon
BACKGROUND: Use of elexacaftor/tezacaftor/ivacaftor (ETI) for treatment of cystic fibrosis (CF) has resulted in unprecedented clinical improvements necessitating development of outcome measures for monitoring disease course. Intranasal micro-optical coherence tomography (μOCT) has previously helped detect and characterize mucociliary abnormalities in patients with CF. This study was done to determine if μOCT can define the effects of ETI on nasal mucociliary clearance and monitor changes conferred to understand mechanistic effects of CFTR modulators beyond CFTR activation...
April 30, 2024: Heliyon
https://read.qxmd.com/read/38680415/overcoming-burkholderia-cepacia-by-successful-eradication-with-clinical-improvement-in-cystic-fibrosis
#5
JOURNAL ARTICLE
Mustafa A Al-Tikrity, Merlin Thomas, Mona Al Langawi, Reem Hasan Mustafa El Ajez
No abstract text is available yet for this article.
2024: Qatar Medical Journal
https://read.qxmd.com/read/38680409/generation-of-human-induced-pluripotent-stem-cells-from-a-patient-with-homozygous-i1234v-mutation-of-cystic-fibrosis
#6
JOURNAL ARTICLE
Mohamed M Emara, Merlin Thomas, Mona Al Langawi, Michail Nomikos, Hanaa Mousa, Soha Aboukhalaf, Nadin H Abouzeid, Yasemin AlShanableh, Maryam K Al Thani, Yehia Y Hussein, Nuha T Swaidan, Yasmin Elsharabassi
No abstract text is available yet for this article.
2024: Qatar Medical Journal
https://read.qxmd.com/read/38679549/echocardiographic-assessment-of-cardiovascular-involvements-in-children-with-cystic-fibrosis
#7
JOURNAL ARTICLE
Hosseinali Ghaffaripour, Ali Reza Norouzi, Maryam Hassanzad, Fariba Alaei, Mohammad Reza Khalilian, Hojjat Derakhshanfar, Nasrin Elahi Mehr
BACKGROUND: Over the past four decades, numerous case reports and clinical studies have highlighted the presence of heart disease in individuals with cystic fibrosis. Given the limited information in this field and the imperative to identify early changes during childhood, our study aims to explore cardiac dysfunction in patients with cystic fibrosis using echocardiography. METHODS: In this case-control study, we examined echocardiographic findings from thirty-three patients with cystic fibrosis and sixty healthy children...
April 27, 2024: Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society
https://read.qxmd.com/read/38679287/a-promoter-dependent-upstream-activator-augments-cftr-expression-in-diverse-epithelial-cell-types
#8
JOURNAL ARTICLE
Giuliana C Coatti, Nirbhayaditya Vaghela, Pulak Gillurkar, Shih-Hsing Leir, Ann Harris
The cystic fibrosis transmembrane conductance regulator (CFTR) gene encodes an anion-selective channel found in epithelial cell membranes. Mutations in CFTR cause cystic fibrosis (CF), an inherited disorder that impairs epithelial function in multiple organs. Most men with CF are infertile due to loss of intact genital ducts. Here we investigated a novel epididymis-selective cis-regulatory element (CRE), located within a peak of open chromatin at -9.5 kb 5' to the CFTR gene promoter. Activation of the -9...
April 27, 2024: Biochimica et Biophysica Acta. Gene Regulatory Mechanisms
https://read.qxmd.com/read/38678689/the-role-of-staphylococcus-aureus-in-cystic-fibrosis-pathogenesis-and-clinico-microbiological-interactions
#9
REVIEW
Elham Sheykhsaran, Amin Abbasi, Mohammad Yousef Memar, Reza Ghotaslou, Hossein Bannazadeh Baghi, Fariba Naeimi Mazraeh, Delara Laghousi, Javid Sadeghi
Cystic fibrosis (CF) is a progressive and inherited disease that affects approximately 70000 individuals all over the world annually. A mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene serves as its defining feature. Bacterial infections have a significant impact on the occurrence and development of CF. In this manuscript, we discuss the role and virulence factors of Staphylococcus aureus as an important human pathogen with the ability to induce respiratory tract infections. Recent studies have reported S...
April 4, 2024: Diagnostic Microbiology and Infectious Disease
https://read.qxmd.com/read/38678203/predicting-lung-function-decline-in-cystic-fibrosis-the-impact-of-initiating-ivacaftor-therapy
#10
JOURNAL ARTICLE
Grace C Zhou, Ziyun Wang, Anushka K Palipana, Eleni-Rosalina Andrinopoulou, Pedro Miranda Afonso, Gary L McPhail, Christopher M Siracusa, Emrah Gecili, Rhonda D Szczesniak
BACKGROUND: Modulator therapies that seek to correct the underlying defect in cystic fibrosis (CF) have revolutionized the clinical landscape. Given the heterogeneous nature of lung disease progression in the post-modulator era, there is a need to develop prediction models that are robust to modulator uptake. METHODS: We conducted a retrospective longitudinal cohort study of the CF Foundation Patient Registry (N = 867 patients carrying the G551D mutation who were treated with ivacaftor from 2003 to 2018)...
April 27, 2024: Respiratory Research
https://read.qxmd.com/read/38678160/aav-vectored-expression-of-monospecific-or-bispecific-monoclonal-antibodies-protects-mice-from-lethal-pseudomonas-aeruginosa-pneumonia
#11
JOURNAL ARTICLE
Jordyn A Lopes, Nicole E Garnier, Yanlong Pei, Jacob G E Yates, Elena S B Campbell, Melanie M Goens, Madison E Hughes, Amira D Rghei, Brenna A Y Stevens, Matthew M Guilleman, Brad Thompson, Cezar M Khursigara, Leonardo Susta, Sarah K Wootton
Pseudomonas aeruginosa poses a significant threat to immunocompromised individuals and those with cystic fibrosis. Treatment relies on antibiotics, but persistent infections occur due to intrinsic and acquired resistance of P. aeruginosa towards multiple classes of antibiotics. To date, there are no licensed vaccines for this pathogen, prompting the urgent need for novel treatment approaches to combat P. aeruginosa infection and persistence. Here we validated AAV vectored immunoprophylaxis as a strategy to generate long-term plasma and mucosal expression of highly protective monoclonal antibodies (mAbs) targeting the exopolysaccharide Psl (Cam-003) and the PcrV (V2L2MD) component of the type-III secretion system injectosome either as single mAbs or together as a bispecific mAb (MEDI3902) in a mouse model...
April 27, 2024: Gene Therapy
https://read.qxmd.com/read/38677887/update-on-the-diagnosis-and-management-of-cystic-fibrosis-pulmonary-exacerbations
#12
REVIEW
Jonathan D Cogen, Bradley S Quon
Pulmonary exacerbations in people with cystic fibrosis are associated with significant morbidity and reduced quality of life. Pulmonary exacerbation treatment guidelines, published by an expert panel assembled by the Cystic Fibrosis Foundation nearly 15 years ago, were primarily consensus-based as there were several gaps in the evidence base. In particular, limited evidence existed regarding optimal pulmonary exacerbation treatment strategies, including duration of antibiotic therapy, treatment location, antibiotic selection, and the role of systemic corticosteroids...
April 27, 2024: Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society
https://read.qxmd.com/read/38677493/the-folding-pathway-of-abc-transporter-cftr-effective-and-robust
#13
JOURNAL ARTICLE
Peter van der Sluijs, Hanneke Hoelen, Andre Schmidt, Ineke Braakman
De novo protein folding into a native three-dimensional structure is indispensable for biological function, is instructed by its amino acid sequence, and occurs along a vectorial trajectory. The human proteome contains thousands of membrane-spanning proteins, whose biosynthesis begins on endoplasmic reticulum-associated ribosomes. Nearly half of all membrane proteins traverse the membrane more than once, including therapeutically important protein families such as solute carriers, G-protein-coupled receptors, and ABC transporters...
April 25, 2024: Journal of Molecular Biology
https://read.qxmd.com/read/38677054/evaluation-of-mixed-biofilm-production-by-candida-spp-and-staphylococcus-aureus-strains-co-isolated-from-cystic-fibrosis-patients-in-northwest-algeria
#14
JOURNAL ARTICLE
Karima Gourari-Bouzouina, Zahia Boucherit-Otmani, Abdelfettah Seghir, Zahira Zakia Baba Ahmed-Kazi Tani, Imene Bendoukha, Abdeselem Benahmed, Mohammed Aissaoui, Kebir Boucherit
Cystic fibrosis patients' lungs are chronically colonized by multiple microbial species capable of forming biofilms. This study aimed to characterize the polymicrobial biofilm formed by Candida spp. and S. aureus, co-isolated from sputum samples of cystic fibrosis patients regarding microbial density, metabolic activity, and structure. 67 samples from 28 patients were collected with a 96% alteration rate. 34% showed alterations by both Candida spp. and Gram-positive bacteria, predominantly Candida spp. and S...
April 26, 2024: Diagnostic Microbiology and Infectious Disease
https://read.qxmd.com/read/38676590/could-the-halp-score-serve-as-a-biomarker-of-bronchiectasis-exacerbation
#15
JOURNAL ARTICLE
Mustafa Çolak, Hikmet Çoban, Nurhan Sarioğlu, Merve Yumrukuz Şenel, Fuat Erel
INTRODUCTION: Bronchiectasis is a chronic inflammatory lung disease and patients may occasionally experience acute exacerbations. Our study aims to determine the relationship between exacerbation periods and HALP (hemoglobin, albumin, lymphocyte, platelet) scores in patients with bronchiectasis. MATERIALS AND METHODS: Adult patients diagnosed with bronchiectasis and followed up in our clinic between 02.2020-12.2022 were retrospectively evaluated. After the examinations, the effect of bronchiectasis exacerbation on the HALP score was investigated...
March 2024: Tüberküloz Ve Toraks
https://read.qxmd.com/read/38676528/substituted-4h-3-1-benzoxazine-4-one-derivatives-as-inhibitors-of-cathepsin-g
#16
JOURNAL ARTICLE
Kholoud F Aliter, Rami A Al-Horani
BACKGROUND: Cathepsin G (CatG) is a cationic serine protease with a wide substrate specificity. CatG has been reported to play a role in several pathologies, including rheumatoid arthritis, ischemic reperfusion injury, acute respiratory distress syndrome, and cystic fibrosis, among others. OBJECTIVE: We aim to develop a new class of CatG inhibitors and evaluate their potency and selectivity against a series of serine proteases. METHODS: We exploited chemical synthesis as well as chromogenic substrate hydrolysis assays to construct and evaluate the new inhibitors...
April 26, 2024: Medicinal Chemistry
https://read.qxmd.com/read/38675780/surface-exposed-protein-moieties-of-burkholderia-cenocepacia-j2315-in-microaerophilic-and-aerobic-conditions
#17
JOURNAL ARTICLE
António M M Seixas, Carolina Silva, Joana M M Marques, Patrícia Mateus, Manuel J Rodríguez-Ortega, Joana R Feliciano, Jorge H Leitão, Sílvia A Sousa
Burkholderia cepacia complex infections remain life-threatening to cystic fibrosis patients, and due to the limited eradication efficiency of current treatments, novel antimicrobial therapies are urgently needed. Surface proteins are among the best targets to develop new therapeutic strategies since they are exposed to the host's immune system. A surface-shaving approach was performed using Burkholderia cenocepacia J2315 to quantitatively compare the relative abundance of surface-exposed proteins (SEPs) expressed by the bacterium when grown under aerobic and microaerophilic conditions...
April 9, 2024: Vaccines
https://read.qxmd.com/read/38675098/novel-dry-hyaluronic-acid-vancomycin-complex-powder-for-inhalation-useful-in-pulmonary-infections-associated-with-cystic-fibrosis
#18
JOURNAL ARTICLE
María S Magi, Yanina de Lafuente, Eride Quarta, María C Palena, Perla Del R Ardiles, Paulina L Páez, Fabio Sonvico, Francesca Buttini, Alvaro F Jimenez-Kairuz
Polyelectrolyte-drug complexes are interesting alternatives to improve unfavorable drug properties. Vancomycin (VAN) is an antimicrobial used in the treatment of methicillin-resistant Staphylococcus aureus pulmonary infections in patients with cystic fibrosis. It is generally administered intravenously with a high incidence of adverse side effects, which could be reduced by intrapulmonary administration. Currently, there are no commercially available inhalable formulations containing VAN. Thus, the present work focuses on the preparation and characterization of an ionic complex between hyaluronic acid (HA) and VAN with potential use in inhalable formulations...
March 22, 2024: Pharmaceutics
https://read.qxmd.com/read/38674745/insights-on-pseudomonas-aeruginosa-carbohydrate-binding-from-profiles-of-cystic-fibrosis-isolates-using-multivalent-fluorescent-glycopolymers-bearing-pendant-monosaccharides
#19
JOURNAL ARTICLE
Deborah L Chance, Wei Wang, James K Waters, Thomas P Mawhinney
Pseudomonas aeruginosa contributes to frequent, persistent, and, often, polymicrobial respiratory tract infections for individuals with cystic fibrosis (CF). Chronic CF infections lead to bronchiectasis and a shortened lifespan. P. aeruginosa expresses numerous adhesins, including lectins known to bind the epithelial cell and mucin glycoconjugates. Blocking carbohydrate-mediated host-pathogen and intra-biofilm interactions critical to the initiation and perpetuation of colonization offer promise as anti-infective treatment strategies...
April 16, 2024: Microorganisms
https://read.qxmd.com/read/38674677/how-does-airway-surface-liquid-composition-vary-in-different-pulmonary-diseases-and-how-can-we-use-this-knowledge-to-model-microbial-infections
#20
REVIEW
Dean Walsh, Jennifer Bevan, Freya Harrison
Growth environment greatly alters many facets of pathogen physiology, including pathogenesis and antimicrobial tolerance. The importance of host-mimicking environments for attaining an accurate picture of pathogen behaviour is widely recognised. Whilst this recognition has translated into the extensive development of artificial cystic fibrosis (CF) sputum medium, attempts to mimic the growth environment in other respiratory disease states have been completely neglected. The composition of the airway surface liquid (ASL) in different pulmonary diseases is far less well characterised than CF sputum, making it very difficult for researchers to model these infection environments...
April 3, 2024: Microorganisms
keyword
keyword
13596
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.